Increasing use of genomics in drugs development and discovery along with rising government funding is expected to drive market expansion in the near future at a CAGR of 12.60% during the forecast period 2023 to 2032.

Market Research Future (MRFR) has published a cooked research report on the “Global Genomics Market” that contains information from 2018 to 2032. 

Market Highlights

The global genomics market is accounted to register a CAGR of 12.60% during the forecast period and is estimated to reach USD 133.845 billion by 2032.

The factors driving the growth of the genomics market are an increase in the use of genomics in research and development (R&D) of new drugs, an increase in global pharmaceutical industry competition, a rise in demand for genetically modified animals and plants, a constant decline in the cost of genetic procedures, market expansion initiatives taken by private and public organizations, an increase in demand for nucleic acid sequencing, and the entry of new players. In addition, the market players for genomics are predicted to benefit from the rise in need for customized medicines and the growing popularity of alliances between research institutions and businesses.

Key Players:

MRFR recognizes the following companies as the key players in the global genomics market - Agilent Technologies; Bio-Rad Laboratories, Inc.; BGI Genomics; Color Genomics, Inc.; Danaher Corporation; Eppendorf AG; Eurofins Scientific; F. Hoffmann-La Roche Ltd.; GE Healthcare; Illumina, Inc.; Myriad Genetics, Inc.; Oxford Nanopore Technologies; Pacific Biosciences of California, Inc.; QIAGEN N.V.; Quest Diagnostics Incorporated; Thermo Fisher Scientific, Inc.; and 23andMe, Inc.

Segment Analysis

The global genomics market has been segmented based application & technology, end-use and deliverables.

On the basis of application & technology, the market is segmented into Functional Genomics, Epigenomics, Pathway Analysis and Biomarker Discovery. The functional genomics segment was attributed to holding the largest market share in 2022. The rising body of research showing how genetic modifications can be used to control cognitive disorders and behaviors has led to this significant market share. There will be a lot more information revealed on how genetic regulation affects disorders like Autism Spectrum Disorder (ASD) in the future.

Based on end-use, the global genomics market has been segmented into Clinical Research, Academic & Government Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Other End Users. The pharmaceutical & biotechnology companies segment was expected to hold the largest market share in 2022. The reason for this is that businesses in the pharmaceutical and biotech sectors are investing heavily and attempting to revolutionise the way healthcare is delivered by improving patient wellbeing and extending life expectancy. Pharma companies are among the main users of applied genomics.

Based on deliverables, the global market has been segmented into Products and Services. The products segment was expected to hold the largest market share in 2022. With the introduction of numerous new products, the genomics market is becoming more competitive. Additionally, there is an increase in the demand for individualized medicine and a drop in DNA sequencing prices, which gave rise to NGS (Next Generation Sequencing) technology and a slew of unique goods.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Genomics Market Research Report

Regional Analysis

The global genomics market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe genomics market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The genomics market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World genomics market comprises of Middle East, Africa, and Latin America.

The largest market share for genomics was maintained by the North American regional sector. This is credited to the assistance of major pharmaceutical companies and research organizations. Due to the effects of genetic expression on human health, genomics is now a crucial component of all illness research and therapeutic development.

Moreover, the Europe market has been persistently growing over the forecast period. The main element fueling the expansion of the industry in the region is the application of government regulations and reimbursement policies. The market in this region is also anticipated to increase as a result of the actions of the up-and-coming market players, including product launches, alliances, mergers, and others.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period due to the rising demand for innovative therapeutic medications to combat the region's rising disease incidence and the growing demand for genomics applications in diagnostics.

Furthermore, the rest of the world's genomics market is divided into the Middle East, Africa, and Latin America. The market in Latin America, the Middle East, and Africa is anticipated to expand significantly as a result of active government backing and an improved healthcare environment. The prevalence of chronic diseases like cancer is also a factor in the growth.

Key Findings of the Study

• The global genomics market is expected to reach USD 133.845 billion by 2032, at a CAGR of 12.60% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market because there is a growing need for novel therapeutic drugs.


• Based on application & technology, the functional genomics segment was attributed to holding the largest market in 2022, with an approximate market share of 40%.


• Agilent Technologies; Bio-Rad Laboratories, Inc.; BGI Genomics; Color Genomics, Inc.; Danaher Corporation; Eppendorf AG; Eurofins Scientific; F. Hoffmann-La Roche Ltd.; GE Healthcare; Illumina, Inc.; Myriad Genetics, Inc.; Oxford Nanopore Technologies; Pacific Biosciences of California, Inc.; QIAGEN N.V.; Quest Diagnostics Incorporated; Thermo Fisher Scientific, Inc.; and 23andMe, Inc.